Lv1
50 积分 2026-02-24 加入
Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic
18天前
已完结
Adjuvant olaparib real world data for BRCA positive, HER2-negative high-risk early breast cancer patients in the United Kingdom
27天前
已完结
[Consensus on recurrence risk and clinical management of HR+/HER-2- early breast cancer (2025 edition)]
1个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
3个月前
已完结
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
3个月前
已完结
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
3个月前
已关闭
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
3个月前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
4个月前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
4个月前
已关闭
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
